Skip to main content
Premium Trial:

Request an Annual Quote

Guardant Inks Liquid Biopsy Assay Deal With Pfizer Oncology

NEW YORK (GenomeWeb) – Guardant Health announced late last week that it has signed an agreement to provide its Guardant360 liquid biopsy cancer assay to Pfizer's oncology business unit, for use in clinical trials.

Guardant360 is a blood-based 73-gene test that investigates actionable somatic alteration across all solid tumor sites to provide clinicians with information to better manage their patients' disease. Under the terms of the non-exclusive deal, the assay will be a Pfizer Oncology preferred circulating tumor DNA test for liquid biopsy specimens.

Additional terms of the deal were not disclosed.

Earlier this year, Guardant formed alliances with Pfizer and three other big pharma companies to develop a new 500-plus-gene liquid biopsy panel for use in clinical trials and cancer drug and immunotherapy development.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.